Friday, 21 Jul 2017

You are here

Ohio Sues Five Pharma Companies Over Opioid Epidemic

Ohio is suing five major drug manufacturers, accusing them of misrepresenting the risks of prescription opioid painkillers that has resulted in the current opioid epidemic. The Attorney General of Ohio, Mike DeWine, wants to hold big Pharma responsible for a deadly and costly opioid crisis.

Prescription opioids, including narcotics and heroin, have been linded to a record number (>33,000) deaths in the United States in 2015, according to the Centers for Disease Control and Prevention. One in 5 people (or 2.3 million) in Ohio were prescribed narcotics last year. Which lead to Ohio having one of the nations highest overdose death rates; 4,169 deaths from overdoses last year alone.

In many instances, the victims were killed by heroin cut with fentanyl, smuggled into the country from Mexico or China, thereby rendering the product 25 to 50 times more potent than heroin and 50 to 100 times more potent than morphine according to the U.S. Drug Enforcement Administration.

The suit asserts the drug companies have violated the Ohio Consumer Sales Practices Act, Ohio Corrupt Practices Act, and committing Medicaid fraud and are guilty of disseminating false and misleading statements.

Companies included in the suit were Janssen Pharmaceuticals, Allergan, Purdue Pharma, Endo and Cephalon. Janssen has responded by stating "The allegations in this lawsuit are both legally and factually unfounded."

Other municipalities, such as West Virginia and Mississippi, have also file suits against Pharma for their opioid promotional practices.

Like the cigarette makers, the drug makers relied on "sales representatives" and influential doctors and "seemingly neutral and credible professional societies and patient advocacy groups" to tout the supposed benefits of long-term opioid use "even though there is no 'good evidence' to support" those claims, the suit states.

The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

FDA Requests Removal of OPANA-ER from the Market

The U.S. Food and Drug Administration has asked Endo International to withdraw Opana ER from the market, stating that benefits no longer outweigh its risks of this long-acting opioid.

A March 2017 advisory committee concluded that Opana ER, is not safe, and many have called for its removal.

Opana ER is twice as potent as oxycodone and has a high abuse potential when crushed and taken for a massive high effect by addicts.  

Non-Prescribed Opioid Abuse by Young Adults

Journal of Addiction Medicine reported that young adults often are "self-medicated" to manage pain.

Spinal Manipulation Equal to NSAIDS for Acute Low Back Pain

JAMA has published a review of 15 RCTs (1711 patients) analyzing the role of spinal manipulation therapy in patients with acute low back pain. The authors found modest improvements in pain and function at up to 6 weeks, with temporary minor musculoskeletal harms.

Lyrica Fails in Sciatica Pain

Lyrica (pregabalin) was first approved in 2004 and since has been studied and approved for use in neuropathic pain (associated with diabetic neuropathy), postherpetic neuralgia, partial onset seizures, fibromyalgia and neuropathic pain with spinal cord injury. It is often used to manage chronic pain and neuropathic pain outside these indications.

Limited Benefits with Intra-Discal Steroid Injections for Back Pain

A a randomized trial published in Annals of Internal Medicine shows that intradiscal glucocorticoid injection has limited (1 month) efficacy in treating low back pain (LBP) associated with active discopathy, yet decreased over time.